In This Section

SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team: Transforming Pancreatic Cancer to a Treatable Disease

Elizabeth M. Jaffee, MD

Elizabeth M. Jaffee, MD

Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Robert H. Vonderheide, MD

Robert H. Vonderheide, MD

Director, Abramson Cancer Center


The pancreatic cancer tumor microenvironment (TME) plays a huge role in pancreatic cancer’s resistance to treatment. The team set out to examine the hypothesis that the immunosuppressive pancreatic cancer milieu can be reprogrammed into an immuno-stimulatory one to enable tumor rejection. They have conducted different clinical trials and established biomarkers of TME reprogramming with each trial, focusing on a novel immune suppressive pathway within the TME and stroma. More recently, they have started a phase I clinical trial on a neoantigen peptide vaccine that incorporates prioritized neoantigens and personalized mesothelin epitopes in pancreatic cancer patients.

Grant News

Dream Team shares results of its clinical studies on the combination of pancreatic tumor vaccines with anti-PD-1.